taken together these findings suggest that the previously observed enhanced potency of systemically administered mk-771 over trh in in vivo central nervous system ( cns ) test paradigms is not likely to be due to a difference in the agonist requirements of cns as compared with pituitary receptors for trh .
C0032002
pituitary
C0040162
trh